Dr. Vikramjit S. Kanwar

Hematology | Oncology
Amc
47 New Scotland Ave, 
Albany, NY 
Amc
47 New Scotland Ave, 
Albany, NY 

Overview

Vikramjit Kanwar is a Hematologist and an Oncologist practicing medicine in Albany, New York.

His clinical expertise encompasses Leukemia, Acute Lymphoblastic Leukemia (ALL), Adult Soft Tissue Sarcoma, and Acute Myeloid Leukemia (AML).

He is actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 24 clinical trials.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in NY

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Amc
47 New Scotland Ave, Albany, NY 12208

Additional Areas of Focus

Dr. Kanwar has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

24 Clinical Trials

A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2026
Intervention Type: Drug, Radiation
Study Drugs: Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2026
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Ganitumab, Ifosfamide, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2026
Intervention Type: Drug, Procedure, Biological, Other, Radiation
Study Drugs: Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Mitoxantrone, Mitoxantrone Hydrochloride, Pegaspargase, Hydrocortisone, Thioguanine, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2026
Intervention Type: Other, Drug, Biological
Study Drugs: Bleomycin, Brentuximab, Cyclophosphamide, Doxorubicin, Etoposide, Methylprednisolone, Prednisone, Vincristine
Study Phase: Phase 3
Neuroblastoma Biology Studies
Neuroblastoma Biology Studies
Enrollment Status: Completed
Publish Date: July 09, 2026
Intervention Type: Other
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Enrollment Status: Completed
Publish Date: June 30, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride, Fluorouracil, Irinotecan Hydrochloride, Temsirolimus, Vincristine Sulfate
Study Phase: Phase 3
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer
Enrollment Status: Completed
Publish Date: June 29, 2026
Intervention Type: Other, Procedure
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Enrollment Status: Completed
Publish Date: June 17, 2026
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Doxorubicin, Ifosfamide, Pazopanib
Study Phase: Phase 2/Phase 3
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Enrollment Status: Completed
Publish Date: June 02, 2026
Intervention Type: Drug, Other, Radiation
Study Drugs: Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD
A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD
Enrollment Status: Completed
Publish Date: June 02, 2026
Intervention Type: Other, Drug
Study Drugs: Asparaginase, Bortezomib, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Sorafenib
Study Phase: Phase 3
View 9 Less Clinical Trials

11 Total Publications

Treatment and Outcome of Children With Neuroblastoma in India: Report From the InPOG-NB-18-01 India Neuroblastoma Registration Study.
Treatment and Outcome of Children With Neuroblastoma in India: Report From the InPOG-NB-18-01 India Neuroblastoma Registration Study.
Journal: Pediatric blood & cancer
Published: March 06, 2026
Similar Doctors
Expertise in
46
conditions
Dr. Makenzi C. Evangelist
Hematology | Oncology
Expertise in
46
conditions
Dr. Makenzi C. Evangelist
Hematology | Oncology
Referral may be required

Albany Medical Center

43 New Scotland Ave, 
Albany, NY 
 (0.1 miles away)
518-262-6696
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Makenzi Evangelist is a Hematologist and an Oncologist practicing medicine in Albany, New York. Dr. Evangelist is highly rated in 46 conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Paget Disease of the Breast, and Non-Small Cell Lung Cancer (NSCLC).

Expertise in
29
conditions
Dr. Rahul Ravilla
Hematology | Oncology
Expertise in
29
conditions
Dr. Rahul Ravilla
Hematology | Oncology
Referral may be required

St. Peter's Health Partners Medical Associates P.C.

400 Patroon Creek Blvd, 
Albany, NY 
 (2.5 miles away)
518-262-6696
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rahul Ravilla is a Hematologist and an Oncologist practicing medicine in Albany, New York. Dr. Ravilla is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Upper Tract Urothelial Carcinoma (UTUC), Clear Cell Sarcoma, Chromophobe Renal Cell Carcinoma, and WT1-Related Wilms Tumor Syndromes.

Expertise in
26
conditions
Dr. Ira L. Zackon
Hematology | Oncology
Expertise in
26
conditions
Dr. Ira L. Zackon
Hematology | Oncology
Referral may be required

Albany Medical Center

43 New Scotland Ave, 
Albany, NY 
 (0.1 miles away)
518-262-6696
Languages Spoken:
English
See accepted insurances

Ira Zackon is a Hematologist and an Oncologist practicing medicine in Albany, New York. Dr. Zackon is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Plasmacytoma, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Vikramjit S. Kanwar

How do I make an appointment with Dr. Vikramjit S. Kanwar?

You can book an appointment with Dr. Vikramjit S. Kanwar by calling their office at 518-262-5513. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Vikramjit S. Kanwar a top-rated expert for Leukemia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Vikramjit S. Kanwar is classified as an Experienced expert for Leukemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Vikramjit S. Kanwar specialize in?

While Dr. Vikramjit S. Kanwar is a Hematology, they have specific expertise in Leukemia, Acute Lymphoblastic Leukemia (ALL), and Adult Soft Tissue Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Vikramjit S. Kanwar participate in research or clinical trials?

Yes. Dr. Vikramjit S. Kanwar has published 11 articles and abstracts on conditions like Leukemia. You can view a list of Dr. Vikramjit S. Kanwar's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kanwar's expertise for a condition
ConditionClose
        View All 12 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile